ClinicalTrials.gg
CompletedNCT03051256Updated Nov 1, 2023Results posted

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

A Phase 2 interventional study of REL-1017 and Placebo in Depressive Disorder, Major and Depressive Disorder, Treatment-Resistant, sponsored by Relmada Therapeutics, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Relmada Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
690th of 1,323
62 · median 70
Started
2018
with 49 others
Phase 2
271 of 1,500
45 open now
Registered
870th of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 690th largest by enrollment of the 1,323 interventional ones that give a count, is one of 50 that started in 2018, is one of 271 in phase 2, and was the 870th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients diagnosed with major depressive disorder (MDD). The patients will be adults with MDD who are diagnosed with a current MDE who have experienced an inadequate response to 1 to 3 courses of treatment with an antidepressant medication. This population will provide the opportunity to compare the safety and efficacy effects of treatment with an approved antidepressant in conjunction with REL-1017 versus the effects of an antidepressant alone. This study includes in-patient and out-patient periods.

Read the detailed description

Currently available medications have proven to be useful for the treatment of depression, but also have limitations including low response rates, a significant number of treatment resistant patients, and time-lag for response, which emphasizes a major unmet need for more efficacious and faster-acting antidepressants. Recent studies have demonstrated that ketamine, a non-competitive glutamate-N-methyl-D-Aspartate (NMDA) receptor antagonist, produces rapid onset (2 hours) and long-lasting (7 days) antidepressant actions in treatment resistant patients. This rapid action, by a mechanism completely different from typical monoamine reuptake inhibitors, represents a significant finding in the field of depression.

Racemic methadone, the 50/50 combination of d-methadone and l-methadone, has been in widespread use for decades and has been studied extensively. Methadone is currently approved for use in the management of severe pain, detoxification treatment of opioid addiction, and maintenance treatment of opioid addiction.

The results of a study evaluating the receptor binding profiles of racemic methadone and its stereoisomers suggest that d-methadone does not essentially contribute to the opioid effect of racemic methadone and that it has a 10 times lower affinity for the mu1, mu2, and delta opioid receptors compared to l-methadone. Racemic methadone and its d- and l isomers exhibit similar affinities for the non-competitive binding site of the NMDA receptor and are non-competitive NMDA receptor antagonists.

In the forced swim test, a rodent behavioral model of antidepressant activity, both ketamine and d-methadone at all doses tested significantly decreased the immobility of the rats compared to the vehicle suggesting antidepressant like activity. Neither drug increased spontaneous locomotor activity.

Relmada has conducted 2 clinical studies to identify the dose levels of REL-1017 (d-methadone) that have little to no opioid effects and that are expected to possess NMDA antagonistic properties for the evaluation of oral REL-1017 in the treatment of MDD and neuropathic pain conditions. Initial Phase 1 single ascending dose and multiple ascending dose clinical studies of REL-1017 were designed to evaluate the safety and tolerance of the pure d methadone isomer in healthy opioid-naïve subjects and identify a safe and potentially effective dose range in this population. These studies showed that REL-1017 was safe and well-tolerated at single oral doses up to 150 mg (maximum tolerated dose) and up to 75 mg administered once daily for 10 days in healthy opioid-naïve subjects.

The pre-clinical and previous clinical experience with REL-1017 (d-methadone) provided the basis for the initiation of the present study, which will extend the evaluation of the safety, tolerability, and PK of REL-1017 at 2 doses with repeated administration to depressed patients. Since REL-1017 is proposed for use as adjunctive therapy in the treatment of patients diagnosed with major depressive disorder (MDD), the patients will be male adults with MDD who are diagnosed with a current depressive episode who have experienced an inadequate response to 1 to 3 courses of treatment with an antidepressant medication.

Based on the safety data from Protocol REL-1017-111, single doses of 5 mg, 20 mg, 60 mg, 100 mg, and 150 mg of REL-1017 or placebo were well tolerated. The results of Protocol REL-1017-112 evaluated 10 days of dosing with 25 mg, 50 mg and 75 mg of REL-1017 or placebo, and no impact on safety was observed. In spite of the confirmed dose proportionality, the comparison of concentration and exposure between the 50 mg and 75 mg REL-1017 treatment groups demonstrated only slight differences. Consequently, 25 mg and 50 mg doses were chosen for administration in Protocol REL-1017-202 as single daily doses over a period of 7 days.

Thus, as a single isomer of racemic methadone, d-methadone has been shown to possess NMDA antagonist properties with virtually no opioid activity or ketamine-like toxicities at the expected therapeutic doses.

In this study, adult male patients with MDD who are diagnosed with a current MDE and who have experienced an inadequate response to 1 to 3 courses of treatment with an antidepressant medication will be randomized to study drug in a 1:1:1 ratio. Approximately 15 patients each will receive REL-1017 25 mg, REL-1017 50 mg, or placebo once daily for 7 days. Endpoints include assessments of safety, tolerability, efficacy and pharmacokinetics of REL-1017. Patients will be required to stay in the clinic for 10 days and will then be followed as an outpatient for 12 additional days.

03

Conditions studied

  • Depressive Disorder, Major
  • Depressive Disorder, Treatment-Resistant

Keywords

  • REL-1017
  • d-Methadone
  • Methadone
  • Depression
  • Refractory Depression
  • Antidepressant
  • Adjunctive Treatment
  • NMDA Receptor Antagonist
  • Excitatory Amino Acid Antagonist
  • Glutamate Antagonist
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males between 18 and 65 years of age, inclusive; and females between 18 and 65 years of age, inclusive, who are >1 year .
  2. Diagnosed with recurrent MDD as defined by the Diagnostic and Statistical Manual, Fifth Edition (), and confirmed by the Mini International Neuropsychiatric Interview, Version 7.0.2 (MINI).
  3. Diagnosed with a current MDE lasting 8 weeks to 36 months as defined by the DSM-5 and confirmed by the MINI.
  4. Treated with an adequate dosage of a SSRI, SNRI, or bupropion during the current MDE for at least 8 weeks prior to Screening with the same, adequate dosage for the last 4 weeks. Minimum adequate doses are defined in the (ATRQ). The maximum dose allowed for paroxetine is 40 mg QD, for fluoxetine is 60 mg QD, and for sertraline is 200 mg QD.
  5. Have experienced an inadequate response to 1 to 3 courses of treatment with an antidepressant medication in the current episode, as defined as \<50% improvement with an antidepressant medication at doses listed on the SAFER Interview Criteria: State versus trait; Assessability; Face validity; Ecological validity; and Rule of three Ps (pervasive, persistent, and pathological).
  6. Hamilton Depression Rating Scale-17 (HAM-D-17) ≥19 at Screening and Check-in (Day -1).
  7. between 18.0 and 35.0 kg/m2, inclusive, and a minimum weight of 50.0 kg.
  8. Per the Investigator's judgment, able to meet all study requirements, including the confined/inpatient portion of the study, adherence with both approved ADT and study drug regimen, and completion of all assessments and all scheduled visits.
  9. Male patients of must be using and willing to continue using medically acceptable , from Screening and for at least 2 months after the last study drug administration.
  10. Must be able to read, speak, and understand English and must provide written prior to the initiation of any protocol-specific procedures.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of abnormality as assessed by physical examination, medical history, 12-lead , vital signs, or laboratory values, which in the opinion of the Investigator would jeopardize the safety of the patient or the validity of the study results, including torsades de pointes, any bradyarrhythmias, or uncompensated heart failure.
  2. Chronic use of prescribed opioids (i.e., >120 days in a 6-month period) up to 6 months prior to Screening or any recreational use of opioids.
  3. Evidence of clinically significant hepatic or renal impairment, including or AST >1.5 x (ULN), >1 x ULN, or endocrine laboratory values (including clinically significant thyroid parameters, i.e., thyroid stimulating hormone [TSH], triiodothyronine [T3], and thyroxine [T4]).
  4. History or family history of sudden unexplained death or long syndrome (measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle).
  5. Any 12-lead ECG with repeated demonstration of QTc ≥450 msec or a QRS interval >120 msec at Screening.
  6. History of clinically diagnosed hypotension requiring treatment.
  7. History or presence of any condition in which an opioid is (e.g., significant respiratory depression, acute or severe bronchial asthma or hypercarbia, bronchitis, or has/is suspected of having paralytic ileus).
  8. No more than 3 prescribed doses of an opioid within the 6 months prior to Screening and no use at all within the last month.
  9. Use of an antipsychotic, anticonvulsant, or mood stabilizer, regardless of indication, within the 3 months prior to Screening.
  10. History of allergy or to methadone or related drugs (e.g., opioids).
  11. Positive test for or . Patients with a positive test may be considered for inclusion with approval from the Medical Monitor.
  12. Any current and primary psychiatric disorder, as defined as a condition that is the primary focus of distress and/or treatment, other than MDD.
  13. Any lifetime history of bipolar I or II disorder, any psychotic disorder, post-traumatic stress disorder, borderline personality disorder, antisocial personality disorder, obsessive compulsive disorder, eating disorder, intellectual disability, or pervasive developmental disorder.
  14. History in the past 12 months of a primary diagnosis of anxiety disorder or panic disorder not related to the current MDE.
  15. Current diagnosis of alcohol or substance use disorder, as defined by , at Screening or within the 12 months prior to Screening. Patients with the following diagnoses within the past 12 months, however, may be included at the Investigator's discretion: mild alcohol use disorder, mild cannabis use disorder, and any severity tobacco use disorder.
  16. A confirmed positive result on the urine drug/alcohol screen at Screening or Check-in. If the urine drug/alcohol screen is positive at Screening, retesting or rescreening may be scheduled with prior approval from the Medical Monitor.
  17. Patients who, in the Investigator's judgment, are at significant risk for suicide. A patient with a Columbia-Suicide Severity Rating Scale (C-SSRS) ideation score of 4 or 5 within the last 6 months or any suicide attempt within the past year must be excluded, as should a patient with an ideation score of 4 or 5 or any suicide attempt at the Check-in or Baseline Visit.
  18. Patients with a 20% improvement between Screening and Check-in (Day -1) on the HAM-D-17.
  19. Patients who did not safely discontinue medications prohibited.
  20. Patients receiving new onset psychotherapy (individual, group, marriage, or family therapy) within 2 months prior to Screening or plans to start at any time during participation in the study.
  21. Patients who have received electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or vagus nerve stimulation (VNS) or who have participated in a ketamine study within the last 6 months.
  22. Patients with any clinically significant neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, chronic pain, or gastrointestinal disorder. Medical conditions that are minor or well-controlled may be permitted if they will not increase the safety risk to the patient or compromise interpretation of the safety or efficacy endpoints.
  23. Patients taking fluvoxamine or St. John's Wort.
  24. Patients who have participated in a clinical study with an medication in the past 6 months, or who have participated in more than 4 clinical studies with investigational medications in the past 2 years.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    REL-1017 25 mg

    REL-1017 75 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 25 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.

    Drug: REL-1017

  • Experimental
    REL-1017 50 mg

    REL-1017 100 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 50 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.

    Drug: REL-1017

  • Placebo comparator
    Placebo

    100 mL Ocean Spray® Diet Cranberry Juice will be administered as a single oral dose daily for 7 days.

    Drug: Placebo

Interventions

  • REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.

    Also known as: d-Methadone

  • DrugPlacebo

    Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (AEs) [Safety and Tolerability]

    Spontaneously reported or observed AEs will be recorded and reported throughout the study, and AEs will be elicited using a non-leading question at every visit from Screening through the Day 21 assessment. An AE was any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and may not necessarily have a causal relationship with the administered treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant laboratory abnormality, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, regardless of relationship to the medicinal (investigational) product. During the study, an AE could also occur outside the time that the investigational product(s) was given (e.g., during the time from discontinuation of prohibited medications).

    Time frame: 21 days

Secondary outcomes

  1. ECG Parameters [Safety]

    12-Lead ECGs will be performed and reported at Screening; at Check In (Day -1); Days 1 through 9; and at Day 14.

    Time frame: Screening, Day -1, Day 1 hour 2, 8, Day 2 hour 2, 8, Day 3-7 hour 2, Day 8, Day 9, and Day 14

  2. Columbia Suicide Severity Rating Scale (C-SSRS) [Safety and Tolerability]

    The C-SSRS will be administered and reported at Screening and Check In (Day -1); and at Days 1, 2, 8, 9 and 14. The C-SSRS is routinely used to quantify the severity of suicidal ideation and behavior. Both the ideation and behavior subscales are sensitive to change over time. The scale identifies behaviors that may be indicative of an individual's intent to commit suicide. This measure contains 6 "yes" or "no" questions in which respondents are asked to indicate whether they have experienced several thoughts or feelings relating to suicide over the past month. Each question addresses a different component of the respondent's suicide ideation severity: (1) Desire to be dead; (2) Suicidal thoughts; (3) Consideration of suicide methods; (4) Formed intent to commit suicide; (5) Completed suicide plan; and (6) Initiated suicide plan. A higher score indicates a higher intensity of suicidal ideation.

    Time frame: Day -1, Day 1, Day 2, Day 8, Day 9 and Day 14

  3. Montgomery-Asberg Depression Scale (MADRS)

    Montgomery-Asberg Depression Scale (MADRS) will be administered and reported on Days 4, 7, and 14. The MADRS questionnaire includes questions on the following symptoms: (1) Apparent sadness; (2) Reported sadness; (3) Inner tension; (4) Reduced sleep; (5) Reduced appetite; (6) Concentration difficulties; (7) Lassitude; (8) Inability to feel; (9) Pessimistic thoughts; (10) Suicidal thoughts. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. In Study REL-1017-202, the MADRS was administered using the Structured Interview Guide for the MADRS (SIGMA). A negative change from baseline indicates improvement.

    Time frame: Change from Baseline to Day 7

  4. Montgomery-Asberg Depression Scale (MADRS)

    Montgomery-Asberg Depression Scale (MADRS) will be administered and reported on Days 4, 7, and 14. The MADRS questionnaire includes questions on the following symptoms: (1) Apparent sadness; (2) Reported sadness; (3) Inner tension; (4) Reduced sleep; (5) Reduced appetite; (6) Concentration difficulties; (7) Lassitude; (8) Inability to feel; (9) Pessimistic thoughts; (10) Suicidal thoughts. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. In Study REL-1017-202, the MADRS was administered using the Structured Interview Guide for the MADRS (SIGMA). A negative change from baseline indicates improvement.

    Time frame: Change from Baseline to Day 14

  5. Symptoms of Depression Questionnaire (SDQ)

    Symptoms of Depression Questionnaire (SDQ) will be administered and reported on Days 4, 7, and 14. The SDQ is a 44-item, self-report scale designed to measure the severity of symptoms across several subtypes of depression. The SDQ was developed to more fully capture the heterogeneity of symptom presentations of depressive disorders than current, widely used scales for MDD. The SDQ includes items that inquire about an extensive number of depressive symptoms beyond the ones included in other commonly used scales. The 44 SDQ items are rated on a 6-point scale. The total score is the sum of 44 items and can range from 44 to 264. A negative change from baseline indicates improvement. 1 = Better than Normal; 2= Normal; 3= Minimally Sad; 4= Moderately Sad; 5= Markedly Sad; 6= Extremely Sad

    Time frame: Change from Baseline to Day 7

  6. Symptoms of Depression Questionnaire (SDQ)

    Symptoms of Depression Questionnaire (SDQ) will be administered and reported on Days 4, 7, and 14. The SDQ is a 44-item, self-report scale designed to measure the severity of symptoms across several subtypes of depression. The SDQ was developed to more fully capture the heterogeneity of symptom presentations of depressive disorders than current, widely used scales for MDD. The SDQ includes items that inquire about an extensive number of depressive symptoms beyond the ones included in other commonly used scales. The 44 SDQ items are rated on a 6-point scale. The total score is the sum of 44 items and can range from 44 to 264. A negative change from baseline indicates improvement. 1 = Better than Normal; 2= Normal; 3= Minimally Sad; 4= Moderately Sad; 5= Markedly Sad; 6= Extremely Sad

    Time frame: Change from Baseline to Day 14

  7. Clinical Global Impressions of Severity (CGI-S)

    Clinical Global Impressions of Severity (CGI-S) will be administered and reported on Days 4, 7, and 14. The CGI-S is a standard method used in clinical studies to quantify and track patient progress and treatment response over time. The scale is composed of 7 ratings: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The score ranges from 1 to 7, and a lower CGI-S score indicates lower levels of depression.

    Time frame: Change from Baseline to Day 7

  8. Clinical Global Impressions of Severity (CGI-S)

    Clinical Global Impressions of Severity (CGI-S) will be administered and reported on Days 4, 7, and 14. The CGI-S is a standard method used in clinical studies to quantify and track patient progress and treatment response over time. The scale is composed of 7 ratings: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The score ranges from 1 to 7, and a lower CGI-S score indicates lower levels of depression.

    Time frame: Change from Baseline to Day 14

  9. Clinical Global Impressions of Improvement (CGI-I)

    Clinical Global Impressions of Improvement (CGI-I) will be administered and reported at Days 4, 7 and 14. The CGI-I is a standard method used in clinical studies to quantify and track patient change over time. The scale is composed of 7 ratings: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse. The score ranges from 1 to 7, and a lower CGI-I score indicates greater improvement in symptoms.

    Time frame: Change from Baseline to Day 7

  10. Clinical Global Impressions of Improvement (CGI-I)

    Clinical Global Impressions of Improvement (CGI-I) will be administered and reported at Days 4, 7 and 14. The CGI-I is a standard method used in clinical studies to quantify and track patient change over time. The scale is composed of 7 ratings: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse. The score ranges from 1 to 7, and a lower CGI-I score indicates greater improvement in symptoms.

    Time frame: Change from Baseline to Day 14

  11. Maximum Observed Plasma Concentration (Cmax) [Pharmacokinetic]

    The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

    Time frame: Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24)

  12. Area Under the Plasma Concentration-time Curve From Time Zero Until the Dosing Interval of 24 Hours (AUCtau) [Pharmacokinetic]

    The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

    Time frame: Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24)

  13. Time to Maximum Observed Plasma Concentration (Tmax) [Pharmacokinetic]

    The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

    Time frame: Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24)

  14. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) [Pharmacokinetic]

    The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

    Time frame: Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24)

  15. Apparent Terminal Elimination Half-life (t½) [Pharmacokinetic]

    The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

    Time frame: Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24) and Day 7 (hour 24, 48, and 168 post last dose)

07

Results

Posted Mar 17, 2021

Participant flow

Participant flow — Overall Study
MilestoneREL-1017 25 mgREL-1017 50 mgPlacebo
Started192122
Completed192121
Not completed001

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Events (AEs) [Safety and Tolerability]

Spontaneously reported or observed AEs will be recorded and reported throughout the study, and AEs will be elicited using a non-leading question at every visit from Screening through the Day 21 assessment. An AE was any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and may not necessarily have a causal relationship with the administered treatment. An AE could therefore be any unfavorable and unintended sign (including a clinically significant laboratory abnormality, for example), symptom, or disease temporally associated with the use of a medicinal (investigational) product, regardless of relationship to the medicinal (investigational) product. During the study, an AE could also occur outside the time that the investigational product(s) was given (e.g., during the time from discontinuation of prohibited medications).

Time frame:
21 days
Reported as:
Count of participants · Participants
Incidence of Treatment Emergent Adverse Events (AEs) [Safety and Tolerability]
ParticipantsREL-1017 25 mgREL-1017 50 mgPlacebo
All-causality TEAEs91512
All-causality SAEs000
SecondaryECG Parameters [Safety]

12-Lead ECGs will be performed and reported at Screening; at Check In (Day -1); Days 1 through 9; and at Day 14.

Time frame:
Screening, Day -1, Day 1 hour 2, 8, Day 2 hour 2, 8, Day 3-7 hour 2, Day 8, Day 9, and Day 14
Reported as:
Count of participants · Participants
ECG Parameters [Safety]
ParticipantsREL-1017 25 mgREL-1017 50 mgPlacebo
Screening — Normal141916
Screening — Abnormal (not clinically significant)526
Screening — Abnormal (clinically significant)000
Day -1 (Check-in) — Normal171920
Day -1 (Check-in) — Abnormal (not clinically significant)222
Day -1 (Check-in) — Abnormal (clinically significant)000
Day 1, 2 hrs post-dose — Normal161820
Day 1, 2 hrs post-dose — Abnormal (not clinically significant)332
Day 1, 2 hrs post-dose — Abnormal (clinically significant)000
Day 1, 8 hrs post-dose — Normal151820
Day 1, 8 hrs post-dose — Abnormal (not clinically significant)432
Day 1, 8 hrs post-dose — Abnormal (clinically significant)000
Day 2, 2 hrs post-dose — Normal151920
Day 2, 2 hrs post-dose — Abnormal (not clinically significant)422
Day 2, 2 hrs post-dose — Abnormal (clinically significant)000
Day 2, 8 hrs post-dose — Normal151919
Day 2, 8 hrs post-dose — Abnormal (not clinically significant)422
Day 2, 8 hrs post-dose — Abnormal (clinically significant)000
Day 3, 2 hrs post-dose — Normal141918
Day 3, 2 hrs post-dose — Abnormal (not clinically significant)523
Day 3, 2 hrs post-dose — Abnormal (clinically significant)000
Day 4, 2 hrs post-dose — Normal151919
Day 4, 2 hrs post-dose — Abnormal (not clinically significant)422
Day 4, 2 hrs post-dose — Abnormal (clinically significant)000
Day 5, 2 hrs post-dose — Normal131917
Day 5, 2 hrs post-dose — Abnormal (not clinically significant)624
Day 5, 2 hrs post-dose — Abnormal (clinically significant)000
Day 6, 2 hrs post-dose — Normal151818
Day 6, 2 hrs post-dose — Abnormal (not clinically significant)433
Day 6, 2 hrs post-dose — Abnormal (clinically significant)000
Day 7, 2 hrs post-dose — Normal151619
Day 7, 2 hrs post-dose — Abnormal (not clinically significant)452
Day 7, 2 hrs post-dose — Abnormal (clinically significant)000
Day 8 — Normal151719
Day 8 — Abnormal (not clinically significant)442
Day 8 — Abnormal (clinically significant)000
Day 9 (Discharge) — Normal141819
Day 9 (Discharge) — Abnormal (not clinically significant)532
Day 9 (Discharge) — Abnormal (clinically significant)000
Day 14 — Normal151718
Day 14 — Abnormal (not clinically significant)323
Day 14 — Abnormal (clinically significant)000
SecondaryColumbia Suicide Severity Rating Scale (C-SSRS) [Safety and Tolerability]

The C-SSRS will be administered and reported at Screening and Check In (Day -1); and at Days 1, 2, 8, 9 and 14. The C-SSRS is routinely used to quantify the severity of suicidal ideation and behavior. Both the ideation and behavior subscales are sensitive to change over time. The scale identifies behaviors that may be indicative of an individual's intent to commit suicide. This measure contains 6 "yes" or "no" questions in which respondents are asked to indicate whether they have experienced several thoughts or feelings relating to suicide over the past month. Each question addresses a different component of the respondent's suicide ideation severity: (1) Desire to be dead; (2) Suicidal thoughts; (3) Consideration of suicide methods; (4) Formed intent to commit suicide; (5) Completed suicide plan; and (6) Initiated suicide plan. A higher score indicates a higher intensity of suicidal ideation.

Time frame:
Day -1, Day 1, Day 2, Day 8, Day 9 and Day 14
Reported as:
Count of participants · Participants
Columbia Suicide Severity Rating Scale (C-SSRS) [Safety and Tolerability]
ParticipantsREL-1017 25 mgREL-1017 50 mgPlacebo
Participants with Suicidal Ideation (Any Score 1-5) : Day -1 (Check-in)105
Participants with Suicidal Ideation (Any Score 1-5) : Day 1 (Baseline)105
Participants with Suicidal Ideation (Any Score 1-5) : Day 2000
Participants with Suicidal Ideation (Any Score 1-5) : Day 8011
Participants with Suicidal Ideation (Any Score 1-5) : Day 9 (Discharge)011
Participants with Suicidal Ideation (Any Score 1-5) : Day 14111
Participants with Suicidal Behavior (any) : Day -1 (Check-in)000
Participants with Suicidal Behavior (any) : Day 1 (Baseline)000
Participants with Suicidal Behavior (any) : Day 2000
Participants with Suicidal Behavior (any) : Day 8000
Participants with Suicidal Behavior (any) : Day 9 (Discharge)000
Participants with Suicidal Behavior (any) : Day 14000
SecondaryMontgomery-Asberg Depression Scale (MADRS)

Montgomery-Asberg Depression Scale (MADRS) will be administered and reported on Days 4, 7, and 14. The MADRS questionnaire includes questions on the following symptoms: (1) Apparent sadness; (2) Reported sadness; (3) Inner tension; (4) Reduced sleep; (5) Reduced appetite; (6) Concentration difficulties; (7) Lassitude; (8) Inability to feel; (9) Pessimistic thoughts; (10) Suicidal thoughts. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. In Study REL-1017-202, the MADRS was administered using the Structured Interview Guide for the MADRS (SIGMA). A negative change from baseline indicates improvement.

Time frame:
Change from Baseline to Day 7
Reported as:
Least squares mean · score on a scale
Montgomery-Asberg Depression Scale (MADRS)
score on a scaleREL-1017 25 mgREL-1017 50 mgPlacebo
Montgomery-Asberg Depression Scale (MADRS)-17.4 ± 2.5-15.9 ± 2.4-8.7 ± 2.3
Statistical analysis
  • REL-1017 25 mg vs Placebo · Mixed Models Analysis · p = <0.0122
  • REL-1017 50 mg vs Placebo · Mixed Models Analysis · p = <0.0308
SecondaryMontgomery-Asberg Depression Scale (MADRS)

Montgomery-Asberg Depression Scale (MADRS) will be administered and reported on Days 4, 7, and 14. The MADRS questionnaire includes questions on the following symptoms: (1) Apparent sadness; (2) Reported sadness; (3) Inner tension; (4) Reduced sleep; (5) Reduced appetite; (6) Concentration difficulties; (7) Lassitude; (8) Inability to feel; (9) Pessimistic thoughts; (10) Suicidal thoughts. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60 with scores above 34 indicating severe depression. In Study REL-1017-202, the MADRS was administered using the Structured Interview Guide for the MADRS (SIGMA). A negative change from baseline indicates improvement.

Time frame:
Change from Baseline to Day 14
Reported as:
Least squares mean · score on a scale
Montgomery-Asberg Depression Scale (MADRS)
score on a scaleREL-1017 25 mgREL-1017 50 mgPlacebo
Montgomery-Asberg Depression Scale (MADRS)-16.8 ± 2.7-17.8 ± 2.6-7.4 ± 2.4
Statistical analysis
  • REL-1017 25 mg vs Placebo · Mixed Models Analysis · p = <0.0103
  • REL-1017 50 mg · Mixed Models Analysis · p = <0.0039
SecondarySymptoms of Depression Questionnaire (SDQ)

Symptoms of Depression Questionnaire (SDQ) will be administered and reported on Days 4, 7, and 14. The SDQ is a 44-item, self-report scale designed to measure the severity of symptoms across several subtypes of depression. The SDQ was developed to more fully capture the heterogeneity of symptom presentations of depressive disorders than current, widely used scales for MDD. The SDQ includes items that inquire about an extensive number of depressive symptoms beyond the ones included in other commonly used scales. The 44 SDQ items are rated on a 6-point scale. The total score is the sum of 44 items and can range from 44 to 264. A negative change from baseline indicates improvement. 1 = Better than Normal; 2= Normal; 3= Minimally Sad; 4= Moderately Sad; 5= Markedly Sad; 6= Extremely Sad

Time frame:
Change from Baseline to Day 7
Reported as:
Least squares mean · score on a scale
Symptoms of Depression Questionnaire (SDQ)
score on a scaleREL-1017 25 mgREL-1017 50 mgPlacebo
Symptoms of Depression Questionnaire (SDQ)-52.4 ± 7.1-52.9 ± 6.6-37.9 ± 6.4
Statistical analysis
  • REL-1017 25 mg vs Placebo · Mixed Models Analysis · p = 0.1237
  • REL-1017 50 mg vs Placebo · Mixed Models Analysis · p = 0.1017
SecondarySymptoms of Depression Questionnaire (SDQ)

Symptoms of Depression Questionnaire (SDQ) will be administered and reported on Days 4, 7, and 14. The SDQ is a 44-item, self-report scale designed to measure the severity of symptoms across several subtypes of depression. The SDQ was developed to more fully capture the heterogeneity of symptom presentations of depressive disorders than current, widely used scales for MDD. The SDQ includes items that inquire about an extensive number of depressive symptoms beyond the ones included in other commonly used scales. The 44 SDQ items are rated on a 6-point scale. The total score is the sum of 44 items and can range from 44 to 264. A negative change from baseline indicates improvement. 1 = Better than Normal; 2= Normal; 3= Minimally Sad; 4= Moderately Sad; 5= Markedly Sad; 6= Extremely Sad

Time frame:
Change from Baseline to Day 14
Reported as:
Least squares mean · score on a scale
Symptoms of Depression Questionnaire (SDQ)
score on a scaleREL-1017 25 mgREL-1017 50 mgPlacebo
Symptoms of Depression Questionnaire (SDQ)-55.0 ± 6.4-58.6 ± 6.0-31.8 ± 5.6
Statistical analysis
  • REL-1017 25 mg vs Placebo · Mixed Models Analysis · p = <0.0066
  • REL-1017 50 mg vs Placebo · Mixed Models Analysis · p = <0.0014
SecondaryClinical Global Impressions of Severity (CGI-S)

Clinical Global Impressions of Severity (CGI-S) will be administered and reported on Days 4, 7, and 14. The CGI-S is a standard method used in clinical studies to quantify and track patient progress and treatment response over time. The scale is composed of 7 ratings: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The score ranges from 1 to 7, and a lower CGI-S score indicates lower levels of depression.

Time frame:
Change from Baseline to Day 7
Reported as:
Least squares mean · score on a scale
Clinical Global Impressions of Severity (CGI-S)
score on a scaleREL-1017 25 mgREL-1017 50 mgPlacebo
Clinical Global Impressions of Severity (CGI-S)-1.7 ± 0.3-1.7 ± 0.3-0.8 ± 0.3
Statistical analysis
  • REL-1017 25 mg vs Placebo · Mixed Models Analysis · p = <0.0245
  • REL-1017 50 mg vs Placebo · Mixed Models Analysis · p = <0.0253
SecondaryClinical Global Impressions of Severity (CGI-S)

Clinical Global Impressions of Severity (CGI-S) will be administered and reported on Days 4, 7, and 14. The CGI-S is a standard method used in clinical studies to quantify and track patient progress and treatment response over time. The scale is composed of 7 ratings: 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The score ranges from 1 to 7, and a lower CGI-S score indicates lower levels of depression.

Time frame:
Change from Baseline to Day 14
Reported as:
Least squares mean · score on a scale
Clinical Global Impressions of Severity (CGI-S)
score on a scaleREL-1017 25 mgREL-1017 50 mgPlacebo
Clinical Global Impressions of Severity (CGI-S)-1.6 ± 0.3-2.0 ± 0.3-0.7 ± 0.3
Statistical analysis
  • REL-1017 25 mg vs Placebo · Mixed Models Analysis · p = <0.0454
  • REL-1017 50 mg vs Placebo · Mixed Models Analysis · p = <0.0043
SecondaryClinical Global Impressions of Improvement (CGI-I)

Clinical Global Impressions of Improvement (CGI-I) will be administered and reported at Days 4, 7 and 14. The CGI-I is a standard method used in clinical studies to quantify and track patient change over time. The scale is composed of 7 ratings: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse. The score ranges from 1 to 7, and a lower CGI-I score indicates greater improvement in symptoms.

Time frame:
Change from Baseline to Day 7
Reported as:
Least squares mean · score on a scale
Clinical Global Impressions of Improvement (CGI-I)
score on a scaleREL-1017 25 mgREL-1017 50 mgPlacebo
Clinical Global Impressions of Improvement (CGI-I)2.4 ± 0.22.3 ± 0.23.2 ± 0.2
Statistical analysis
  • REL-1017 25 mg vs Placebo · Mixed Models Analysis · p = 0.0177
  • REL-1017 50 mg vs Placebo · Mixed Models Analysis · p = 0.0072
SecondaryClinical Global Impressions of Improvement (CGI-I)

Clinical Global Impressions of Improvement (CGI-I) will be administered and reported at Days 4, 7 and 14. The CGI-I is a standard method used in clinical studies to quantify and track patient change over time. The scale is composed of 7 ratings: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse. The score ranges from 1 to 7, and a lower CGI-I score indicates greater improvement in symptoms.

Time frame:
Change from Baseline to Day 14
Reported as:
Least squares mean · score on a scale
Clinical Global Impressions of Improvement (CGI-I)
score on a scaleREL-1017 25 mgREL-1017 50 mgPlacebo
Clinical Global Impressions of Improvement (CGI-I)2.6 ± 0.32.3 ± 0.33.3 ± 0.3
Statistical analysis
  • REL-1017 25 mg vs Placebo · Mixed Models Analysis · p = 0.0895
  • REL-1017 50 mg vs Placebo · Mixed Models Analysis · p = 0.0109
SecondaryMaximum Observed Plasma Concentration (Cmax) [Pharmacokinetic]

The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

Time frame:
Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24)
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) [Pharmacokinetic]
ng/mLREL-1017 25 mgREL-1017 50 mg
Maximum Observed Plasma Concentration (Cmax) [Pharmacokinetic]254.5 ± 60.864343.9 ± 112.36
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero Until the Dosing Interval of 24 Hours (AUCtau) [Pharmacokinetic]

The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

Time frame:
Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24)
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero Until the Dosing Interval of 24 Hours (AUCtau) [Pharmacokinetic]
h*ng/mLREL-1017 25 mgREL-1017 50 mg
Area Under the Plasma Concentration-time Curve From Time Zero Until the Dosing Interval of 24 Hours (AUCtau) [Pharmacokinetic]3533 ± 1082.24531 ± 1344.7
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) [Pharmacokinetic]

The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

Time frame:
Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24)
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) [Pharmacokinetic]
hoursREL-1017 25 mgREL-1017 50 mg
Time to Maximum Observed Plasma Concentration (Tmax) [Pharmacokinetic]1.917 (0.950 to 6.00)2.250 (1.00 to 6.02)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) [Pharmacokinetic]

The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

Time frame:
Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24)
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) [Pharmacokinetic]
h*ng/mLREL-1017 25 mgREL-1017 50 mg
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) [Pharmacokinetic]7114 ± 2685.210190 ± 5627.6
SecondaryApparent Terminal Elimination Half-life (t½) [Pharmacokinetic]

The pharmacokinetic parameters of REL-1017 25 mg and 50 mg will be evaluated on Day 1 through Day 7, Day 8, Day 9, and Day 14 where the data allow.

Time frame:
Day 1 (hour -1, 1, 2, 4, 6, 8, 12, and 24) and Day 7 (hour 24, 48, and 168 post last dose)
Reported as:
Mean · h
Apparent Terminal Elimination Half-life (t½) [Pharmacokinetic]
hREL-1017 25 mgREL-1017 50 mg
Day 130.60 ± 18.73931.74 ± 18.888
Day 743.88 ± 11.62138.16 ± 3.9399

Adverse events

Collected over 21 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REL-1017 25 mg0/19 (0%)0/19 (0%)9/19 (47.4%)
REL-1017 50 mg0/21 (0%)0/21 (0%)15/21 (71.4%)
Placebo0/22 (0%)0/22 (0%)12/22 (54.5%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventREL-1017 25 mgREL-1017 50 mgPlacebo
ConstipationGastrointestinal disorders1/193/213/22
HeadacheNervous system disorders2/193/213/22
DiarrheaGastrointestinal disorders0/190/213/22
DyspepsiaGastrointestinal disorders2/190/210/22
NauseaGastrointestinal disorders1/192/212/22
Back PainMusculoskeletal and connective tissue disorders1/192/210/22
Weight DecreaseInvestigations0/192/210/22
Abdominal DiscomfortGastrointestinal disorders0/190/212/22
SomnolenceNervous system disorders1/191/212/22
Upper Respiratory InfectionInfections and infestations0/190/212/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)REL-1017 25 mgREL-1017 50 mgPlaceboTotal
<=18 years0000
Between 18 and 65 years19212262
>=65 years0000
Age, Continuous
Age, Continuous(years)REL-1017 25 mgREL-1017 50 mgPlaceboTotal
Mean49.4 ± 12.448.6 ± 10.949.7 ± 11.149.2 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)REL-1017 25 mgREL-1017 50 mgPlaceboTotal
Female891128
Male11121134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REL-1017 25 mgREL-1017 50 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American13131339
White67922
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)REL-1017 25 mgREL-1017 50 mgPlaceboTotal
United States19212262
BMI
BMI(kg/m^2)REL-1017 25 mgREL-1017 50 mgPlaceboTotal
Mean27.66 ± 3.3327.66 ± 529.02 ± 4.2728.15 ± 4.26
08

Study locations

10 sites
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845-2506, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92103, United States
  • Innovative Clinical Research, Inc
    Hialeah, Florida 33012, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • St. Louis Clinical Trials, LLC
    Saint Louis, Missouri 63141, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417-3445, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
09

References and documents

Publications

  • Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, Alimonti A, Bettini E, Mangano RM, Wessel T, de Somer M, Caron J, Vitolo OV, DiGuglielmo GR, Gilbert A, Mehta H, Kearney M, Mattarei A, Gentilucci M, Folli F, Traversa S, Inturrisi CE, Manfredi PL. REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. Am J Psychiatry. 2022 Feb;179(2):122-131. doi: 10.1176/appi.ajp.2021.21020197. Epub 2021 Dec 22. PubMed 34933568 ↗
  • Guidetti C, Serra G, Pani L, Pappagallo M, Maglio G, Martin S, Mattarei A, Folli F, Manfredi PL, Fava M. Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder. Prim Care Companion CNS Disord. 2023 Feb 14;25(1):22m03267. doi: 10.4088/PCC.22m03267. PubMed 36821775 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jul 2019, 14 months.

Results were first posted in Mar 2021, 1 year 7 months after primary completion.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 14 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2017
First posted
Feb 13, 2017
StartActual
May 11, 2018
Primary completionActual
Jul 30, 2019
CompletionActual
Sep 30, 2019
Results first posted
Mar 17, 2021
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03051256
Lead sponsor
Relmada Therapeutics, Inc.
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Feb 13, 2017
Start date
May 11, 2018
Primary completion
Jul 30, 2019
Completion
Sep 30, 2019
Results posted
Mar 17, 2021
Last update
Nov 1, 2023

Study contacts

Maurizio Fava, MD
study chair · KOL / Advisor

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D-methadone

Start the discussion